Back to results
US 6,136,307 AGranted
Reovirus for the treatment of cellular proliferative disorders
AssigneeOncolytics Biotech Inc.
InventorsPatrick W. K. Lee, James Strong, Matthew C. Coffey
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOncolytics Biotech Inc.
InventorsPatrick W. K. Lee, James Strong, Matthew C. Coffey
Estimating the term…
Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
A method of treating a ras-mediated proliferative disorder in a mammal suffering from said disorder, wherein said mammal is selected from the group consisting of dogs, cats, sheep, goats, cattle, horses, pigs, humans and non-human primates, and wherein said method comprises administering to said mammal an effective amount of at least one reovirus in the absence of BCNU under conditions which result in substantial lysis of the ras-mediated proliferating cells in said mammal.
A method of treating a ras-mediated proliferative disorder in a mammal wherein said mammal is selected from the group consisting of dogs, cats, sheep, goats, cattle, horses, pigs, humans and non-human primates, and wherein said method comprises administering to the ras-mediated proliferating cells of the mammal an effective amount of at least one modified reovirus under conditions which result in substantial lysis of the ras-mediated proliferating cells.
A method of treating a ras-mediated neoplasm in a human, comprising administering to the neoplasm an effective amount of reovirus to result in substantial oncolysis of the cells of the neoplasm.
A method of inhibiting ras-mediated metastases of a neoplasm in a mammal wherein said mammal is selected from the group consisting of dogs, cats, sheep, goats, cattle, horses, pigs, humans and non-human primates, and wherein said method comprises administering to the neoplastic cells of said mammal a reovirus in an amount sufficient to result in substantial lysis of the neoplastic cells.
A method of treating a suspected ras-mediated neoplasm in a mammal, comprising surgical removal of substantially all of the neoplasm and administration of a reovirus to the site of the surgical removal in an amount sufficient to result in substantial oncolysis of any remaining neoplastic cells.
A pharmaceutical composition comprising a reovirus, a chemotherapeutic agent and a pharmaceutically acceptable excipient with the proviso that the chemotherapeutic agent is not BCNU.
A kit comprising a pharmaceutical composition comprising a reovirus and a chemotherapeutic agent with the proviso that the chemotherapeutic agent is not BCNU.
Dependencies are inferred from the claim text.